Clinicopathologic features of V600E and V600K melanoma - Letter

Clinical Cancer Research

Volumn 18, Issue 24, 2012, Pages 6792-

  Jewell, Rosalyn ^a   Chambers, Philip ^a   Harland, Mark ^a   Laye, Jon ^a   Conway, Caroline ^a   Mitra, Angana ^a   Elliott, Faye ^a   Cook, Martin G ^c   Boon, Andy ^b   Newton Bishop, Julia ^a  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b LEEDS TEACHING HOSPITALS NHS TRUST   (United Kingdom)

^c UNIVERSITY OF SURREY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

B RAF KINASE; B RAF KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE;

ADULT; BRAF GENE; CANCER PROGNOSIS; CANCER SURVIVAL; CAUSAL ATTRIBUTION; GENDER; GENE MUTATION; GENOTYPE; HUMAN; LETTER; LONG TERM EXPOSURE; MALE; MELANOMA; MUTATIONAL ANALYSIS; ONCOGENE; OVERALL SURVIVAL; PRIORITY JOURNAL; PYROSEQUENCING; SENESCENCE;

FEMALE; HUMANS; MALE; MELANOMA; PROTO-ONCOGENE PROTEINS B-RAF;

EID: 84871239553     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-2974     Document Type: Letter

References (4)

1. Menzies AM, Haydu LE, Visintin L, Carlino MS, Howle JR, Thompson JF, et al. Distinguishing clinicopathologic features of patients with V600E and V600K BRAF-mutant metastatic melanoma. Clin Cancer Res 2012;18:3242-9.
2. Edlundh-Rose E, Egyhazi S, Omholt K, Mansson-Brahme E, Platz A, Hansson J, et al. NRAS and BRAF mutations in melanoma tumors in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Melanoma Res 2006;16:471-8. (Pubitemid 44934704)
3. Ellerhorst JA, Greene VR, Ekmekcioglu S, Warneke CL, Johnson MM, Cooke CP, et al. Clinical correlates of NRAS and BRAF mutations in primary human melanoma. Clin Cancer Res 2011;17:229-35.
4. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004;116:855-67. (Pubitemid 38410730)